Related Experiment Video

Updated: Jul 17, 2026

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
09:28

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

Developments in urologic oncology "OncoForum": The best of 2017

F Gómez-Veiga1, A Alcaraz-Asensio2, J Burgos-Revilla3

  • 1Servicio de Urología, Hospital Universitario de Salamanca, Grupo de Investigación Traslacional de Urología GITUR, Instituto de Investigación Biomédica de Salamanca IBSAL, Salamanca, España.

Actas Urologicas Espanolas
|June 25, 2018
PubMed
Abstract

Insights

New urologic oncology findings show adjuvant sunitinib benefits high-risk kidney cancer patients. For advanced urothelial cancer, pembrolizumab offers durable responses. Prostate cancer treatments vary in efficacy and adverse events.

Area of Science:

  • Urologic Oncology
  • Medical Oncology
  • Clinical Practice Updates

Background:

  • Key advancements in urologic oncology impact clinical practice.
  • Focus on prostate, kidney, and bladder cancers.

Purpose of the Study:

  • To present significant findings from major 2017 urologic oncology meetings.
  • Highlight research with potential clinical practice implications.

Main Methods:

  • Review of abstracts from 2016 major oncology congresses (EAU, AUA, ASCO, ESMO, ASTRO).
  • Inclusion of high-impact publications as evaluated by the OncoForum committee.

Main Results:

  • Adjuvant sunitinib demonstrated benefit in high-risk recurrent renal cell carcinoma post-nephrectomy.
  • Pembrolizumab showed durable responses in cisplatin-ineligible advanced urothelial cancer.
  • Localized prostate cancer: surgery had more adverse events than observation; no significant mortality difference.
  • Advanced prostate cancer: Androgen-deprivation therapy (ADT) plus abiraterone and prednisolone improved survival compared to ADT alone.
  • Metastatic castration-resistant prostate cancer (mCRPC) post-abiraterone: enzalutamide showed activity with a median radiographic progression-free survival of 8.1 months.

Conclusions:

  • Adjuvant sunitinib is beneficial for high-risk renal cell carcinoma patients.
  • Surgery for localized prostate cancer did not significantly reduce mortality compared to observation.
  • ADT plus abiraterone and prednisolone significantly improved overall and failure-free survival in advanced prostate cancer.
  • Enzalutamide remains an active treatment option for mCRPC previously treated with abiraterone.
Keywords:
Bladder cancerCáncer de próstataCáncer de vejigaCáncer renalKidney cancerProstate cancer

More Related Videos

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma06:39

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Published on: November 22, 2019

Culture of Bladder Cancer Organoids as Precision Medicine Tools08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations01:26

Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations

Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
Urologic Endoscopic Procedure: Cystoscopic Examination01:28

Urologic Endoscopic Procedure: Cystoscopic Examination

Meaning of Cystoscopic Examination:Cystoscopy is an essential diagnostic tool in urology that is used to assess the structure and function of the genitourinary system. It provides a direct view of the urethra, bladder, and, in some cases, the ureteral openings. This procedure helps detect structural abnormalities, infections, cancers, and blockages in the urinary tract. There are two types of cystoscopy:Flexible cystoscopy is commonly performed in outpatient settings due to its less invasive...